RadNet’s Aidence Artificial Intelligence (AI) Subsidiary and Google Health Enter into ...

LOS ANGELES, Nov. 28, 2022 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services today reported that its lung artificial intelligence subsidiary, Aidence, and Google Health, a division of Alphabet, Inc. (NASDAQ: GOOG), announce an agreement to license Google Health’s AI research model for lung nodule malignancy prediction on CT imaging. Aidence will develop, validate and bring this model to the market to support the early and accurate diagnosis of lung cancer and the reduction of unnecessary procedures in screening programs.

Lung cancer screening with low-dose CT has been shown to significantly reduce lung cancer mortality by as high as 24% for men and 33% for women, according to the 2020 NELSON trial. Screening initiatives are increasingly being implemented in Europe, such as the UK’s Targeted Lung Health Checks. In the United States, eligibility criteria have recently been broadened, further reflecting the benefit of lung cancer screening.

A major difficulty in lung cancer screening is establishing the nature of detected lung nodules. Most of these nodules are not cancerous. However, properly identifying and diagnosing such nodules can be time-consuming, costly, anxiety-inducing for patients and their families and sometimes invasive, requiring follow-up CTs or surgical interventions.

Dr Raymond Osarogiagbon, Chief Scientist, Baptist Memorial Health Care Corporation and Director, Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee, explained, “One of the most exciting developments in contemporary population healthcare is the early detection of lung cancer. Unfortunately, the reality that most such nodules will be benign represents a real challenge that cries out for a technological solution. Artificial intelligence is one such solution.”

Dr Osarogiagbon continued, “The world looks forward to the rapid development and validation of software that will enhance our ability to find the many lung cancer needles in the giant haystack that is CT-detected lung nodules in today’s clinical practice.”

Deep learning, a subset of AI, has been shown to support the risk scoring of lung nodule malignancy. In a study published in Nature in 2018, scientists affiliated with Google Health presented a highly accurate model for malignancy classification, consistently matching the performance of experienced radiologists.

Aidence has also built a deep learning model for this purpose. Aidence’s algorithm successfully predicts lung cancer from a single scan and was awarded in the 2017 Kaggle challenge. Its robust performance was later confirmed in a clinical study comparing its performance to that of 11 radiologists on 300 cases.

Aidence and Google Health intend to complete an AI application for lung nodule malignancy prediction. In this collaboration, Google Health will provide its scientific expertise. Aidence will further develop the model into a solution for clinical practice and bring it to market, complying with relevant data privacy requirements and regulatory standards. The development of this AI application is a statement of intent and no regulatory market applications have been made and no orders for sale are being taken.

Outside of this collaboration with Google Health, Aidence has a proven track record of deploying AI in hospitals and clinics across Europe. Its application, Veye Lung Nodules, is currently running in over 80 routine practice and lung cancer screening sites.

Mark-Jan Harte, Aidence co-founder and CEO, said, “Our mission at Aidence is to give lung cancer patients a fighting chance. This strategic partnership with Google Health allows us to accelerate and expand our efforts toward achieving it.”

Mr. Harte continued, “We are enthusiastic about working on a powerful deep learning model for lung nodule malignancy prediction based on the work of the Aidence and Google teams, as well as making sure that all the other requirements that contribute to the successful deployment of AI in clinical practice are in place, like clinical validation, certification and integration into the clinical workflow.”

Akib Uddin, Product Manager at Google Health, commented, “At Google Health, we want to be an active, catalytic force in demonstrating the real-world benefits of AI in health. We know just how important lung cancer screening is in saving lives, and we are excited to play a role in driving impact at scale by enabling great partners like Aidence with our research.”

About RadNet, Inc.

RadNet, Inc., is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 349 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey and New York. Together with affiliated radiologists, inclusive of full-time and per diem employees and technologists, RadNet has a total of approximately 9,000 employees. For more information, visit http://www.radnet.com.

About Google Health

A division of Alphabet, Inc., Google Health is our company-wide effort to help billions of people be healthier. We work toward this vision by meeting people in their everyday moments and empowering them to stay healthy and partnering with care teams and the public health community to provide more accurate, accessible and equitable care. Our teams are applying our expertise and technology to improve health outcomes globally – with high-quality information and tools to help people manage their health and wellbeing, solutions to transform care delivery, research to catalyze the use of artificial intelligence for the screening and diagnosis of disease and data and insights to the public health community. https://health.google/

CONTACTS:

RadNet, Inc.

Mark Stolper, 310-445-2800

Executive Vice President and Chief Financial Officer